
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd is a commercial-stage biopharmaceutical company focused on monoclonal antibody therapies for viral infectious diseases. Their lead mAb PEMGARDA, approved for pre-exposure prevention of COVID-19 in immunocompromised individuals, has shown superiority to mRNA vaccines. The company's next-generation mAb VYD2311, in P3 development, aims to protect a larger target population and is expected to read out by YE2026. With a solid clinical foundation and a promising pipeline, we view Invivyd as a strong investment opportunity, though it faces the usual risks of drug development.
Bears say
Invivyd is a biopharmaceutical company focused on developing monoclonal antibody therapies for viral infectious diseases, with its lead product, PEMGARDA, receiving emergency use authorization for COVID-19. However, only about 56% of treatment days have been recorded for their ongoing Phase 2 trial for Long COVID and COVID-19 post-vaccination syndrome, and management acknowledges the complexity of these conditions. The potential for high-risk, high-upside from SPEAR's positive results is overshadowed by its uncertain success and the company's reliance on one product for revenue.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares